179 related articles for article (PubMed ID: 31429097)
1. Increased risk of thiopurine-related adverse events in elderly patients with IBD.
Calafat M; Mañosa M; Cañete F; Ricart E; Iglesias E; Calvo M; Rodríguez-Moranta F; Taxonera C; Nos P; Mesonero F; Martín-Arranz MD; Mínguez M; Gisbert JP; García-López S; de Francisco R; Gomollón F; Calvet X; Garcia-Planella E; Rivero M; Martínez-Cadilla J; Argüelles F; Arias L; Cimavilla M; Zabana Y; Domènech E;
Aliment Pharmacol Ther; 2019 Oct; 50(7):780-788. PubMed ID: 31429097
[TBL] [Abstract][Full Text] [Related]
2. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
3. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
4. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
[TBL] [Abstract][Full Text] [Related]
5. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
Macaluso FS; Renna S; Maida M; Dimarco M; Sapienza C; Affronti M; Orlando E; Rizzuto G; Orlando R; Ventimiglia M; Cottone M; Orlando A
Scand J Gastroenterol; 2017 Sep; 52(9):981-987. PubMed ID: 28554266
[TBL] [Abstract][Full Text] [Related]
6. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
7. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
9. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
Govani SM; Higgins PD
J Crohns Colitis; 2010 Oct; 4(4):444-9. PubMed ID: 21122542
[TBL] [Abstract][Full Text] [Related]
10. Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort.
Qiu Y; Mao R; Zhang SH; Li MY; Guo J; Chen BL; He Y; Zeng ZR; Chen MH
Medicine (Baltimore); 2015 Oct; 94(41):e1513. PubMed ID: 26469893
[TBL] [Abstract][Full Text] [Related]
11. Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy.
Selinger CP; Rosiou K; Broglio G; Lever G; Chiu CM; Stocker LJ; Chipeta H; Glanville T
Expert Opin Drug Saf; 2023; 22(11):1091-1097. PubMed ID: 37417244
[TBL] [Abstract][Full Text] [Related]
12. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
13. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
14. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
15. Safety of thiopurines in the treatment of inflammatory bowel disease.
de Jong DJ; Derijks LJ; Naber AH; Hooymans PM; Mulder CJ
Scand J Gastroenterol Suppl; 2003; (239):69-72. PubMed ID: 14743886
[TBL] [Abstract][Full Text] [Related]
16. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Bastida G; Alvarez-Sotomayor D; Aguas M; Iborra M; Del Hoyo J; Béjar-Serrano S; Garrido-Marín A; Valero-Pérez E; Nos P
Gastroenterol Hepatol; 2024 May; 47(5):473-480. PubMed ID: 38072359
[TBL] [Abstract][Full Text] [Related]
18. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
[TBL] [Abstract][Full Text] [Related]
20. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
Jharap B; Seinen ML; de Boer NK; van Ginkel JR; Linskens RK; Kneppelhout JC; Mulder CJ; van Bodegraven AA
Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]